The global dry eye treatment devices market size is


New York, Oct. 21, 2022 (GLOBE NEWSWIRE) — announces the release of the report “Global Dry Eye Treatment Devices Market Size, Share & Industry Trends Analysis Report By Technology, By End User, By Regional Outlook and Forecast, 2022 – 2028” –
It is considered a complex tear film and ocular surface disorder with a range of signs and symptoms. Itching, irritation, burning, eye strain and eye inflammation are some of the symptoms, which can range from mild to severe and can potentially damage the cornea, conjunctiva and even loss of sight.

Therefore, treatment should be tailored to each patient focusing on the distinct mechanisms related to their condition, based on different presentations and pathophysiology. Several remedies and medical methods are either on the market or in research for the management of DED. There is a disturbance in the production, assimilation and drainage of tears when the eye is unable to generate enough tears of acceptable quality.

Dry eye is the term for the disease that occurs when the eye develops an adequate volume of tears, but these tears are unable to adequately lubricate the eye, defend against infection, or monitor the healing of the surface of the eye. the eye (DED). One of the most common problems in ophthalmology is dry eye.

Hyperemia, low tear lakes, a period of rapid breakup of tears, and meibomian gland disease are some symptoms that may appear. Slit lamp examinations with and without various dyes, such as fluorescein, rose bengal, and lissamine green, are used to make diagnoses. Schirmer’s test, tear break-up time, tear function index, and functional visual acuity are other tests.

COVID-19 Impact Analysis

The pandemic is expected to harm the growth of the dry eye treatment devices market. The use of dry eye treatment devices has plummeted due to the cancellation and postponement of elective procedures to minimize the spread of viruses. With the eyes serving as a gateway for the virus, the deployment of restrictive measures has also led to the closure of commercial activities, which has reduced the number of patients. However, after restrictions are removed and treatments continue, an increase in the number of dry eye patients may lead to an increase in demand for treatment devices.

Market growth factor

An increase in the number of eye care facilities

Dry eye syndrome (DES) is a chronic disease caused by inadequate tear production and maintenance, which results in a variety of symptoms that differ from person to person. The number of people suffering from dry eye has recently increased due to various causes, which has led to an increase in eye care facilities. The number of specialists working in the field of eye care is steadily increasing and ophthalmologists are expected to continue to be in demand. Vision loss is becoming a significant public health issue as population demographics continue to change.

High incidence and high prevalence of dry eye disease

Dry eye is an extremely common and underdiagnosed eye condition. It is problematic not only because of the symptoms it causes, but also because it is very expensive. Patients with dry eyes experience uncomfortable dry eye symptoms including burning, stinging, gritty feeling, soft tissue feeling, watery eyes, eye fatigue and dryness because their tear film is unstable and unable to maintain the protective qualities required for its structure and function. . The prevalence of dry eye syndrome has increased in recent years; it is a widespread disease.

Market restraining factor

Complications and Pain of DED Therapy

DED is considered an incurable condition that requires constant care to restore and maintain balance in the ocular surface system. Whereas DED symptoms are usually exacerbated by conditions such as blepharitis, diabetes, thyroid problems, rheumatoid arthritis, systemic lupus, and Sjögren’s syndrome. Patient education is an essential first step in the effective management of DED. Patients should be informed by ophthalmologists that DED is a chronic condition that requires ongoing care. It is possible for problems to develop either immediately after treatment or afterwards.

Technology outlook

On the basis of technology, the dry eye treatment devices market is segmented into Broadband Light (BBL), Intense Pulsed Light (IPL), Meibomian Gland Expression (MGX), and Combination (MGX+IPL) . The Intense Pulsed Light (IPL) segment generated a major revenue share in the dry eye treatment devices market in 2021. It is anticipated that the proactive efforts of market players to strengthen their distribution networks through the through alliances and partnerships will contribute to the expansion of the segment.

End User Perspectives

Based on end-use, the dry eye treatment devices market is divided into hospitals, eye clinics, and others. The ophthalmic clinics segment recorded the highest revenue share in the dry eye treatment devices market in 2021. An ophthalmologist is a physician who focuses on the identification and treatment of eye diseases. Ophthalmologists who are subspecialists typically have training that allows them to treat complex eye disorders, involve a particular aspect of the eye, or affect particular populations.

Regional outlook

Regionally, the Dry Eye Treatment Devices market is analyzed across North America, Europe, Asia Pacific and LAMEA. North America got the highest revenue share in the dry eye treatment devices market in 2021. This is due to the high prevalence of dry eye, increasing R&D expenditures and a increase in the number of ophthalmology conferences and trade shows held in the United States. and Canada. Dry eye disease (DED) is becoming more common in the United States, increasing the demand for advanced treatments.

The market research report covers the analysis of major market players. Key companies profiled in the report include MiBo Medical Group, Sight Sciences, Inc., Lumenis Ltd., ESW Vision SAS, Johnson & Johnson Vision Care, Inc., and Alcon, Inc.

Scope of the study

Market Segments Covered in the Report:

By technology

• Meibomian gland expression (MGX)

• Broadband light (BBL)

• Intense Pulsed Light (IPL)

• Combination (MGX+IPL)

Per end user

• Ophthalmology clinics

• Hospitals

• Others

By geography

• North America

o United States

o Canada

o Mexico

o Rest of North America

• Europe

o Germany

o United Kingdom

o France

o Russia

o Spain

o Italy

o Rest of Europe

• Asia Pacific

o China

o Japan

o India

o Australia

o South Korea

o Singapore

o Rest of Asia-Pacific


o Brazil

o Argentina


o Saudi Arabia

o South Africa

o Nigeria

o Rest of the LAMEA

Profiled companies

• MiBo Medical Group

• Vision Sciences, Inc.

• Lumenis Ltd.

• ESW Vision SAS

• Johnson & Johnson Vision Care, Inc.

• Alcon, Inc.

Unique offers

• Comprehensive coverage

• The largest number of tables and figures on the market

• Subscription-based model available

• Best price guaranteed

• Support for after-sales research provided with 10% free customization
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.



Source link

Comments are closed.